Generic Name and Formulations:
Ethiodized oil 480mg/mL; oil for intralymphatic, intrauterine or intra-arterial inj; contains organically combined iodine with ethyl esters of fatty acids of poppy seed oil.
Indications for LIPIODOL:
For use in: hysterosalpingography in adults, selective hepatic intra-arterial use for imaging tumors in adults with hepatocellular carcinoma (HCC), or lymphography in children and adults.
Hysterosalpingography: inject in 2mL increments into endometrial cavity with fluoroscopic control until tubal patency determined; re-image after 24hrs to establish contrast agent has entered peritoneal cavity. Lymphography: inject into lymphatic vessel over ≥1.25hrs (max rate 0.2mL/min) under radiologic monitoring; re-image after 24 or 48hrs to evaluate nodal architecture; (upper extremities): inject 2–4mL; (lower extremities): 6–8mL; (penile): 2–3mL; (cervical): 1–2mL. HCC: inject 1.5–15mL (based on tumor size) slowly under radiologic monitoring; discontinue when stagnation or reflux evident; max dose 20mL. See full labeling.
Lymphography: inject 1–6mL according to anatomical area; max 0.25mL/kg. See full labeling.
Hysterosalpingography: pregnancy, uterine bleeding and endocervicitis, acute pelvic inflammatory disease, marked cervical erosion, immediate pre- or postmenstrual phase or within 30 days of curettage or conization. Lymphography: right to left cardiac shunt, advanced pulmonary disease, tissue trauma or hemorrhage advanced neoplastic disease with expected lymphatic obstruction, previous surgery interrupting the lymphatic system, radiation therapy to examined area. HCC: areas of liver where bile ducts are dilated unless external biliary drainage performed prio to injection. For all: hyperthyroidism, traumatic injuries, and recent hemorrhage or bleeding.
For intralymphatic, intrauterine and selective hepatic intra-arterial use only.
Severely impaired lung function, cardiorespiratory failure, right-sided cardiac overload, sensitivity to other iodinated contrast agents, bronchial asthma, allergic disorders: avoid. Perform radiological monitoring during injection. Avoid intravasation. Monitor for hypersensitivity reactions during and for ≥30mins after administration. Exacerbation of portal hypertension, hepatic ischemia, hepatic failure. Do not exceed recommended dose. Latent hyperthyroidism, Hashimoto thyroditis, history of thyroid irradiation; may affect thryoid diagnostic results for up to 2yrs post-lymphography. Screen for renal dysfunction prior to intra-arterial use; consider follow-up assessments if history of renal dysfunction. Pregnancy (Cat.C). Nursing mothers: not recommended.
Radiopaque contrast agent.
May interfere with iodine-based diagnostic tests and radiotherapy.
Hypersensitivity reactions, pulmonary embolism, pulmonary dysfunction, exacerbation of liver disease, procedural complications, abdominal pain, fever, nausea, vomiting, thyroid dysfunction.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Link Identified Between Cured Meat and Mania in Bipolar Disorder
- Early Risk Factors for Bipolar Disorder Found in Offspring of BD Parents
- First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes
- Daily Drinking Associated With Increased Mortality Risk
- Probiotics, Depression, and the Role of Inflammation
- The Opioid System: The Foundation for Social Risk and Reward
- Correctional Psychiatry: Challenges and Rewards
- Those Left Behind: Working With Suicide-Bereaved Families
- Is Mandatory Reporting of Child Maltreatment in the Best Interests of the Child?
- The Impact of Deafness on Hallucinations and Delusions
- High Risk for Anxiety, Depression, and Stress Observed Among Single Mothers
- Self-Harm, Suicidality Among Adolescents Associated With Poor Outcomes, Recurrent Clinical Care
- Moderate Association Between Sociocognitive Functioning and Thought Disorder in Schizophrenia
- Psychotropic Medications May Improve Pregnancy Outcomes in Bipolar Disorder
- Schizophrenia Polygenetic Risk Score as a Predictor of Bipolar Disorder With Psychosis